Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...
The study, published by the McCullough Foundation, says the deaths reported in VAERS are estimated to be underreported by a ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...
At the 2025 World Economic Forum, FP Events convened global experts to discuss the policy planning, coordination, and investment priorities needed to unlock more equitable, wide-reaching access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results